开发用于阿尔茨海默病的血蛋白分类模型,使用多种机器学习方法
Amy Tsurumi1, Catherine M Cahill2, Andy J Liu3,4
1Department of Surgery, Massachusetts General Hospital and Harvard Medical School, 55 Fruit St., Boston, MA 02114, USA.
International journal of molecular sciences
|December 11, 2025
概括
新阿尔茨海默病 (AD) 检测使用血生物标志物和机器学习进行准确,非侵入性诊断. 已识别的蛋白质,如ANG-2和EGF,对早期检测和潜在的治疗有很大的前景.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 计算生物学 计算生物学
背景情况:
- 阿尔茨海默病 (AD) 诊断依赖于侵入性脑脊液 (CSF) 生物标志物,导致患者的不适.
- 当前检测方法的局限性对有效的AD管理提出了挑战.
- 基于等离子体的生物标志物提供了一个不那么侵入性的,更具成本效益的诊断替代品.
研究的目的:
- 开发和验证用于使用血蛋白质组数据检测AD的机器学习模型.
- 确定与阿尔茨海默病相关的新型血蛋白生物标志物.
- 探索已识别的生物标志物在AD病原和衰老中的相关性.
主要方法:
- 利用了来自AD患者和认知正常个体的120个血蛋白的数据集.
- 应用各种机器学习算法 (EBlasso,EBEN,XGBoost,LightGBM,TabNet,TabPFN) 来进行分类.
- 进行了基因本体学,途径丰富和文献审查,以评估生物标志物的相关性.
主要成果:
- 机器学习模型实现了高诊断性能 (AUROC和精度>0.9).
- 一贯识别的预测蛋白包括angiopoietin-2 (ANG-2),EGF,IL-1α和PDGF-BB,它们与AD有已确定的联系.
- 识别的生物标志物池被与衰老相关的蛋白质显著丰富 (p=0.040).
结论:
- 尖端算法增强了基于等离子体的AD预测模型的开发.
- 这些已识别的蛋白质可能成为阿尔茨海默病的新型治疗或预防点.
- 在不同人群中进行外部验证至关重要,以确认这些发现的概括性.
更多相关视频
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.9K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.2K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
